Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 4/20 | 0.59 |
| ▸ | ANO1 | Q5XXA6 | 15/20 | 0.58 |
| ▸ | ANO2 | Q9NQ90 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144923 | 1.00 | CXCR2 (0.60) | CXCR2MAPTSMN1; SMN2TP53ANO1 | |
| SCHEMBL4147431 | 0.99 | CXCR2 (0.61) | CXCR2MAPTSMN1; SMN2TP53ANO1 | |
| SCHEMBL4156808 | 0.84 | MAPT (0.68) | MAPTSMN1; SMN2TP53ALDH1A1HPGD | |
| SCHEMBL4132719 | 0.84 | MAPT (0.68) | MAPTSMN1; SMN2TP53ALDH1A1HPGD | |
| SCHEMBL4141551 | 0.83 | CNR2 (0.50) | CXCR2MAPTSMN1; SMN2TP53ANO1 | |
| SCHEMBL18506927 | 0.82 | CXCR2 (0.62) | CXCR2MAPTSMN1; SMN2ANO1ALDH1A1 | |
| SCHEMBL4140828 | 0.82 | ANO1 (0.70) | MAPTSMN1; SMN2TP53ANO1ANO2 | |
| SCHEMBL20922566 | 0.82 | CXCR2 (0.61) | CXCR2MAPTSMN1; SMN2ANO1ALDH1A1 | |
| SCHEMBL4132190 | 0.82 | ANO1 (0.70) | MAPTSMN1; SMN2TP53ANO1ANO2 | |
| SCHEMBL4132192 | 0.81 | ANO1 (0.76) | MAPTSMN1; SMN2TP53ANO1ANO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1802634-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044826-A2 | THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143411-A1 | Thiophens and Their Use as Anti-Tumor Agents | TP53, BRDT, VHL | CXCR2 3591/4885MAPT 1629/4885SMN1; SMN2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.